Pharmacogenomics; Sequencing

2A - Pharmacogenomics: From Sequencing to the Clinic
CME (AMA PRA Category 1 Credits™) 1.5; ACPE (UAN: 0853-9999-17-055-L01-P) 1.5; CEU (NSGC Category 1) 0.15; Attendance CEU 1.5

Monday, October 9
1:20 PM - 2:50 PM

Pharmacogenomics research is leading the way to the translation of pharmacogenomics to clinical practice. This session will focus on pharmacogenomics research that is being implemented into patient care.

Learning Objectives:

Liewei Wang

Professor of Pharmacology Co-Director Mayo Pharmacogenomics Program
Mayo Clinic

Liewei Wang, MD, received her MD degree from FuDan University, Shanghai, China, followed by a PhD. degree from the Mayo Graduate School, with an emphasis on cancer biology and cancer pharmacology. Currently, she is a Professor of the Department of Molecular Pharmacology and Experimental Therapeutics at Mayo Clinic.

Dr. Wang has developed a research program with a focus on the use of high throughput genomic technology including array based and next generation sequencing methods, joined with a cell-based model system that consists of 300 lymphoblastoid cell lines, to study mechanisms of cancer biology and antineoplastic drug resistance, both chemotherapy and radiation therapy. In addition to her career-long involvement in pharmacogenomics, she also has extensive experience in functional genomics. She is involved in many clinical translational studies which help identify and understand biomarkers associated with clinical response to endocrine therapy and chemotherapy in breast cancer patients.

Dr. Wang is a member of several key programs at Mayo including: the Mayo-NIH Comprehensive Cancer Center (MCCC) and the Mayo Center for Individualized Medicine (CIM). She is also Co-Principal Investigator and the leader of the Functional Genomics Group for the Mayo-NIH Pharmacogenetics Research Network (PGRN) and the Co-Director for the Pharmacogenomics Program in the Mayo CIM.

Presentation(s):

Send Email for Liewei Wang

Steve Scherer

Professor
Baylor College of Medicine

Steve Scherer is a Professor in the Human Genome Sequencing Center and Department of Molecular and Human Genetics at Baylor College of Medicine. After earning a B.A. in Biology at Colorado College, he worked in the oil business for six years as an engineer in various Middle Eastern countries while based in Europe. He earned his Ph.D. in molecular biology from the Biochemistry Department at Baylor College of Medicine (BCM) under the mentorship of Dr. C. Thomas Caskey where he worked to clone the mouse gene encoding ornithine transcarbamylase and characterize its regulatory regions with the goal of eventual gene therapy in OTC-deficient kids. After a short postdoctoral fellowship at BCM and another at the National Institutes of Health in molecular neuroscience, Dr. Richard Gibbs, Director of the Human Genome Sequencing Center, recruited Dr. Scherer back to BCM in 1997 as the Center's first faculty hire. Dr. Scherer led the mapping group and served as the international chromosome coordinator for chromosomes 3 & 12 through the Human Genome Project. He has served in numerous roles in the HGSC and developed broad collaborations throughout the Texas Medical Center in the fields of bladder and thyroid cancer, hearing loss, smoking cessation, cardiomyopathy, thoracic aneurysms and dissections, dyslipidemia and a variety comparative genomics projects. Dr. Scherer currently heads up the Center's efforts in Pharmacogenomics.

Presentation(s):

Send Email for Steve Scherer

Suzette J. Bielinski

Associate Professor of Epidemiology
Mayo Clinic

Suzette J. Bielinski, MEd, PhD, Associate Professor of Epidemiology, Mayo Clinic College of Medicine and Science. Dr. Bielinski received a Bachelor of Science degree at the College of Saint Catherine, and a Master's degree in Education and Ph.D. in Epidemiology with a minor in Human Genetics at the University of Minnesota. She was a National Institutes of Health Cardiovascular Disease Genetic Pre-doctoral and Post-doctoral Fellow at the University of Minnesota and joined Mayo Clinic in 2008. Dr. Bielinski's research program focuses on the molecular biomarkers of cardiovascular disease with funding from the National Institutes of Health and the Mayo Foundation. Dr. Bielinski has been at the forefront of Mayo Clinic's interactions with several important cardiovascular cohort studies and consortia including the Atherosclerosis Risk in Communities (ARIC), Coronary Artery Risk Development in Young Adults (CARDIA) Study, and Multi-Ethnic Study of Atherosclerosis (MESA). She is a leader of the Mayo Clinic's Right Drug, Right Dose, Right Time - Using Genomic Data to Individualize Treatment (RIGHT Protocol) Study that is designed to implement pharmacogenomic sequence data into clinical systems to improve patient outcomes. The RIGHT Protocol is a collaboration between the Mayo Clinic Centers for Individualized Medicine and Science of Health Care Delivery. Notably, this collaboration with over 11,000 participants, is one of the largest and most extensive preemptive pharmacogenomic studies in the world.

Presentation(s):

Send Email for Suzette Bielinski

J Steven Leeder

Children's Mercy Hospital

J. Steven Leeder, PharmD, PhD, is the Marion Merrell Dow/Missouri Endowed Chair in Pediatric Clinical Pharmacology and Director, Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation at Children's Mercy Kansas City (CMKC), Kansas City, Missouri. He also serves as Associate Chair-Research, Department of Pediatrics and Deputy Director of the Children's Research Institute at CMKC, and holds faculty appointments as Professor of Pediatrics and Pharmacology at the University of Missouri-Kansas City; Courtesy Professor of Pharmaceutical Chemistry in the School of Pharmacy at the University of Kansas (Lawrence, KS); and Clinical Professor of Pediatrics at the University of Kansas Medical Center (Kansas City, KS).
Dr. Leeder is an elected member of the American Pediatric Society, and has served in different capacities for several academic and professional organizations, including the Drug Metabolism and Pharmacogenomics Sections of the International Union of Pharmacology (IUPHAR), the American Society for Pharmacology and Experimental Therapeutics (ASPET), the American Board of Clinical Pharmacology, the American Society for Clinical Pharmacology and Therapeutics (ASCPT), and the International Society for the Study of Xenobiotics (ISSX). He is an Associate Editor for Drug Metabolism and Disposition, on the editorial boards of the journals Pharmacogenomics, and serves as a member of the Executive Committee for the ASPET Board of Publication Trustees.
Dr. Leeder's research focuses on the application of pharmacogenetic and pharmacogenomic strategies to characterize the relative contributions of ontogeny, genetic variation, and disease to observed variability in drug disposition and response in children. Clinical application of this research is embodied in the GOLDILOKs initiative at CMH: Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids.

Presentation(s):

Send Email for J Steven Leeder


Assets

2A - Pharmacogenomics: From Sequencing to the Clinic
CME (AMA PRA Category 1 Credits™) 1.5; ACPE (UAN: 0853-9999-17-055-L01-P) 1.5; CEU (NSGC Category 1) 0.15; Attendance CEU 1.5



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Pharmacogenomics: From Sequencing to the Clinic
CME (AMA PRA Category 1 Credits™) 1.5; ACPE (UAN: 0853-9999-17-055-L01-P) 1.5; CEU (NSGC Category 1) 0.15; Attendance CEU 1.5